Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$61.61 0.0%	$61.05	$43.70 ▼ $86.53	$1.96B	-1.48	49,350 shs	20,004 shs
EWTX Edgewise Therapeutics	$13.99 -2.3%	$15.24	$10.60 ▼ $38.12	$1.47B	0.36	1.18 million shs	797,753 shs
KURA Kura Oncology	$5.55 -1.1%	$6.17	$5.41 ▼ $23.48	$480.49M	0.5	1.20 million shs	807,895 shs
RXRX Recursion Pharmaceuticals	$4.39	$5.00	$3.79 ▼ $12.36	$1.78B	0.99	13.55 million shs	23.11 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-0.03%	-8.44%	+2.38%	+5.75%	+35.26%
EWTX Edgewise Therapeutics	-2.30%	-4.11%	-10.78%	-46.99%	-18.47%
KURA Kura Oncology	-1.07%	-10.48%	-14.75%	-27.45%	-74.17%
RXRX Recursion Pharmaceuticals	0.00%	+7.33%	-24.83%	-42.76%	-51.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLTE Belite Bio	2.1379 of 5 stars	3.5	3.0	0.0	1.9	0.8	0.6
EWTX Edgewise Therapeutics	3.2634 of 5 stars	4.4	2.0	0.0	3.1	3.3	0.0
KURA Kura Oncology	4.4179 of 5 stars	4.5	2.0	4.7	3.2	0.8	0.6
RXRX Recursion Pharmaceuticals	1.7003 of 5 stars	3.2	1.0	0.0	1.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	3.00	Buy	$96.67	56.90% Upside
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$40.22	187.51% Upside
KURA Kura Oncology	2.93	Moderate Buy	$24.50	341.44% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.60	73.12% Upside

Current Analyst Ratings Breakdown

Latest KURA, RXRX, BLTE, and EWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/15/2025	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/15/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
5/6/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
5/2/2025	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $11.00
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
4/29/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00 ➝ $28.00
4/28/2025	KURA Kura Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/21/2025	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$43.00 ➝ $43.00
4/10/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$10.00 ➝ $8.00
4/8/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$3.28 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.53 per share	N/A
KURA Kura Oncology	$67.99M	7.07	N/A	N/A	$5.35 per share	1.04
RXRX Recursion Pharmaceuticals	$59.82M	29.83	N/A	N/A	$1.98 per share	2.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$31.63M	-$1.36	N/A	N/A	N/A	N/A	-31.94%	-30.73%	8/8/2025 (Estimated)
EWTX Edgewise Therapeutics	-$100.16M	-$1.55	N/A	N/A	N/A	N/A	-26.83%	-25.67%	8/14/2025 (Estimated)
KURA Kura Oncology	-$152.63M	-$2.10	N/A	N/A	N/A	N/A	-44.09%	-39.57%	8/14/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$328.07M	-$1.77	N/A	N/A	N/A	-579.52%	-76.56%	-55.68%	8/14/2025 (Estimated)

Latest KURA, RXRX, BLTE, and EWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million
3/17/2025	Q4 2024	BLTE Belite Bio	-$0.30	-$0.32	-$0.02	-$0.32	N/A	N/A
3/3/2025	Q4 2024	EWTX Edgewise Therapeutics	-$0.39	-$0.42	-$0.03	-$0.42	N/A	N/A
2/28/2025	Q4 2024	RXRX Recursion Pharmaceuticals	-$0.36	-$0.53	-$0.17	-$0.53	$19.04 million	$4.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	30.73	30.73
EWTX Edgewise Therapeutics	N/A	26.35	26.35
KURA Kura Oncology	0.02	11.47	11.47
RXRX Recursion Pharmaceuticals	0.04	4.35	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
EWTX Edgewise Therapeutics	N/A
KURA Kura Oncology	N/A
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
EWTX Edgewise Therapeutics	23.20%
KURA Kura Oncology	6.40%
RXRX Recursion Pharmaceuticals	15.75%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
EWTX Edgewise Therapeutics	60	105.20 million	71.86 million	Optionable
KURA Kura Oncology	130	86.58 million	73.49 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.50 million	329.18 million	Optionable

KURA, RXRX, BLTE, and EWTX Headlines

Recent News About These Companies

70,802 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Man Group plc

May 28 at 3:51 AM | marketbeat.com

RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?

May 27 at 11:01 AM | zacks.com

3 Monster Stocks to Hold for the Next 10 Years

May 26 at 8:05 PM | fool.com

Two Sigma Investments LP Grows Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 26 at 4:25 AM | marketbeat.com

Deutsche Bank AG Raises Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 26 at 3:34 AM | marketbeat.com

Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Increased Net Loss Despite Rising Sales

May 24, 2025 | finance.yahoo.com

These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio (RXRX)

May 22, 2025 | marketbeat.com

Rafferty Asset Management LLC Cuts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 21, 2025 | marketbeat.com

Raiffeisen Bank International AG Buys New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 19, 2025 | marketbeat.com

Lazard Asset Management LLC Has $3.76 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 19, 2025 | marketbeat.com

Softbank Group CORP. Invests $99.15 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 18, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Northern Trust Corp

May 17, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (RXRX) Nosedives 36.55% As AI Drug Discovery Dreams Stall

May 15, 2025 | insidermonkey.com

Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock

May 15, 2025 | zacks.com

Recursion Pharmaceuticals: High-Risk Play Getting Riskier By The Quarter

May 14, 2025 | seekingalpha.com

Recursion Pharmaceuticals, Inc. (RXRX): Among the Best Artificial Intelligence Stocks Under $50 to Buy Now

May 14, 2025 | msn.com

Laurion Capital Management LP Invests $16.61 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 14, 2025 | marketbeat.com

Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?

May 12, 2025 | fool.com

2 Top Artificial Intelligence (AI) Stocks to Buy Right Now

May 11, 2025 | fool.com

Leerink Partnrs Has Bullish Estimate for RXRX Q2 Earnings

May 10, 2025 | marketbeat.com

Raymond James Financial Inc. Acquires New Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

May 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA, RXRX, BLTE, and EWTX Company Descriptions

Belite Bio NASDAQ:BLTE

$61.61 -0.02 (-0.03%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$61.84 +0.23 (+0.37%)

As of 05/28/2025 04:04 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Edgewise Therapeutics NASDAQ:EWTX

$13.99 -0.33 (-2.30%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$13.98 -0.01 (-0.04%)

As of 05/28/2025 06:31 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Kura Oncology NASDAQ:KURA

$5.55 -0.06 (-1.07%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$5.58 +0.04 (+0.63%)

As of 05/28/2025 05:11 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.39 0.00 (0.00%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$4.56 +0.17 (+3.76%)

As of 05/28/2025 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time